FTC approves final settlement on generic drug divestiture
The Federal Trade Commission gave final approval to a settlement that satisfies its concerns that Impax Laboratories Inc.’s purchase of CorePharma would be anticompetitive....
Subscription required to view this article.This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: